首页> 外文期刊>International Journal of Nanomedicine >Novel multi-biotin grafted poly(lactic acid) and its self-assembling nanoparticles capable of binding to streptavidin
【24h】

Novel multi-biotin grafted poly(lactic acid) and its self-assembling nanoparticles capable of binding to streptavidin

机译:新型多生物素接枝聚乳酸及其可与链霉亲和素结合的自组装纳米颗粒

获取原文
           

摘要

Abstract: Targeted drug delivery requires novel biodegradable, specific binding systems with longer circulation time. The aim of this study was to prepare biotinylated poly(lactic acid) (PLA) nanoparticles (NPs) which can meet regular requirements as well conjugate more biotins in the polymer to provide better binding with streptavidin. A biotin-graft-PLA was synthesized based on previously published biodegradable poly(ethylene glycol) (PEG)-graft-PLA, with one polymer molecule containing three PEG molecules. Newly synthesized biotin-graft-PLA had three biotins per polymer molecule, higher than the previous biotinylated PLA (≤1 biotin per polymer molecule). A PEG with a much lower molecular weight (MW ~1900) than the previous biotinylated PLA (PEG MW ≥3800), and thus more biocompatible, was used which supplied good nonspecific protein-resistant property compatible to PEG-graft-PLA, suggesting its possible longer stay in the bloodstream. Biotin-graft-PLA specifically bound to streptavidin and self-assembled into NPs, during which naproxen, a model small molecule (MW 230 Da) and hydrophobic drug, was encapsulated (encapsulation efficiency 51.88%). The naproxen-loaded NPs with particle size and zeta potential of 175 nm and —27.35 mV realized controlled release within 170 hours, comparable to previous studies. The biotin-graft-PLA NPs adhered approximately two-fold more on streptavidin film and on biotin film via a streptavidin arm both in static and dynamic conditions compared with PEG-graft-PLA NPs, the proven nonspecific protein-resistant NPs. The specific binding of biotin-graft-PLA NPs with streptavidin and with biotin using streptavidin arm, as well as its entrapment and controlled release for naproxen, suggest potential applications in targeted drug delivery.
机译:摘要:靶向药物输送需要新型的可生物降解的,特定的结合系统以及更长的循环时间。这项研究的目的是制备能够满足常规要求的生物素化聚乳酸(PLA)纳米颗粒(NPs),并在聚合物中缀合更多生物素以提供与链霉亲和素的更好结合。基于先前公开的可生物降解的聚(乙二醇)(PEG)-接枝-PLA合成生物素-接枝-PLA,其中一个聚合物分子包含三个PEG分子。新合成的生物素接枝PLA每个聚合物分子具有三个生物素,高于以前的生物素化PLA(每个聚合物分子≤1个生物素)。使用比以前的生物素化PLA(PEG MW≥3800)低得多的分子量(MW〜1900),因此具有更高的生物相容性的PEG,它提供了与PEG-graft-PLA相容的良好非特异性蛋白抗性。可能更长久地停留在血液中。生物素-移植物-PLA与链霉亲和素特异性结合并自组装成NP,在此期间,将萘普生(一种模型小分子(分子量230 Da)和疏水性药物)包封(包封效率51.88%)。与以前的研究相比,纳普生负载的NPs的粒径和zeta电位为175 nm和-27.35 mV可以在170小时内实现控释。与PEG-移植物-PLA NPs(已证实的非特异性蛋白抗性NPs)相比,在静态和动态条件下,生物素-移植物-PLA NPs在链霉亲和素膜上和通过链霉亲和素臂在生物素膜上的粘附力大约高两倍。生物素移植物-PLA NP与链霉亲和素的特异性结合以及使用链霉亲和素臂与生物素的特异性结合,以及其对萘普生的包封和控释,表明了在靶向药物递送中的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号